NEWS
IMPRESS leads the way for cancer precision medicine
IMPRESS Norway, a national clinical study for cancer precision medicine, will begin in 2021.
State budget: 61,3 million to personalized medicine
These are some of the main points for cancer innovation in the newly released state budget.
Largest biotech agreement ever made in Norway
Our member Vaccibody signs multi-million-dollar agreement.
The new frontier in cancer innovation
Oslo Cancer Cluster (OCC) Innovation Park and Incubator plans to expand by 5o ooo m² in the coming years.
Clinical studies - important for Norwegian companies
Clinical trials in Norway is important for Norwegian companies
Accelerating cancer research with data sharing
A new Norwegian technology enables cancer researchers to more easily share data
Welcome first-year students
The school collaboration days were a little bit different this year ...
Ministers meet at Oslo Cancer Cluster
The corona pandemic and international trade were on the top of the agenda when Nordic ministers met at OCC.
Lytix Biopharma signs licensing agreement
Our member Lytix Biopharma has entered into a milestone agreement